Levers Health Review
Best for: patients interested in GLP-1 microdosing for longevity
Levers Health (Levers Health LLC) offers compounded semaglutide (from $247/mo) and tirzepatide (from $296/mo), plus low-dose/microdose GLP-1 for longevity. Positioned as personalized performance medicine.
Medium confidence · Last verified 2026-04-10 via WebFetch · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Levers Health is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Levers Health prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded Semaglutide | compounded | $247 |
| Compounded Tirzepatide | compounded | $296 |
| Low/Microdose GLP-1 | compounded | $246 |
✓ Pros
- •Named LLC entity
- •Microdose GLP-1 option for longevity
- •Both semaglutide and tirzepatide
✗ Cons
- •No LegitScript or PCAB accreditation
- •No physical address disclosed
- •State availability not disclosed
- •FAQ/terms pages return 404
- •Above-average pricing ($247–$296/mo)
Ready to start with Levers Health?
Starting at $246/month. See current pricing and start your free consultation.
Sources & methodology
Our Levers Health review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Levers Health
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Ready to start with Levers Health?
Starting at $246/month. See current pricing and start your free consultation.